Improving the treatment of parkinson's disease: A novel approach by modulating 5-HT1A receptors

Aging and Disease

Volumn 4, Issue 1, 2013, Pages 1-13

  Shimizu, Saki ^a   Ohno, Yukihiro ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

5 HT1A receptors; Anxiety; Cognitive impairment; Depression; Extrapyramidal motor disorders; Parkinson's disease

Indexed keywords

PARKINSONIA;

EID: 84880939501     PISSN: None     EISSN: 21525250     Source Type: Journal    
DOI: None     Document Type: Review

References (88)

1. Samii A, Nutt JG, Ransom BR (2004). Parkinson's disease. Lancet, 363:1783-1793.
2. Gallagher DA, Schrag A (2012). Psychosis, apathy, depression and anxiety in Parkinson's disease. Neurobiol Dis, 46:581-589.
3. Meireles J, Massano J (2012). Cognitive impairment and dementia in Parkinson's disease: clinical features, diagnosis, and management. Front Neurol, 3:88.
4. Roth BL (1994). Multiple serotonin receptors: Clinical and experimental aspects. Annals of Clinical Psychiatry, 6:67-78.
5. Baumgarten HG, Grozdanovic Z (1995). Psychopharmacology of central serotonergic systems. Pharmacopsychiatry, 2:73-79.
6. Barnes NM, Sharp T (1999). A review of central 5-HT receptors and their function. Neuropharmacology, 38:1083-1152.
7. Ohno Y, Tatara A, Shimizu S, Sasa M (2012). Management of cognitive impairments in schizophrenia: the therapeutic role of 5-HT receptors. In: Sumiyoshi T, editor. Schizophrenia Research: Recent Advances., New York, Nova Science Publishers, Inc, 321-335.
8. 1A receptors in the treatment of schizophrenia and Parkinson's disease. CNS Neurosci Ther, 17:58-65.
9. Ohno Y (2002). Tandospirone citrate, a new serotonergic anxiolytic agent: A potential use in Parkinson's disease. In: Mizuno Y, Fisher A, Hanin A, editors. Mapping the progress of Alzheimer's and Parkinson's disease. New York, Kluwer Academic/Plenum, 423-428.
10. 1A receptors in central nervous system disorders. Cent Nerv Syst Agents Med Chem, 10:148-157.
11. (1A) receptors mediate an increase in locomotor activity in the monoamine-depleted rat. Psychopharmacology (Berl), 163:85-94.
12. 1A agonist, tandospirone, in rats. Biog Amines, 8:329-338.
13. 1A agonist, ameliorates movement disorder via non-dopaminergic systems in rats with unilateral 6-hydroxydopamine-generated lesions. Brain Res, 1112:126-133.
14. 1A agonists using the mouse pole test. Prog Neuropsychopharmacol Biol Psychiatry, 32:1302-1307.
15. Ohno Y, Shimizu S, Imaki J, Ishihara S, Sofue N, Sasa M, Kawai Y. (2008). Anticataleptic 8-OH-DPAT preferentially counteracts with haloperidol-induced Fos expression in the dorsolateral striatum and the core region of the nucleus accumbens. Neuropharmacology, 55:717-723.
16. 1A agonistic anxiolytic agent, on haloperidol-induced catalepsy and forebrain Fos expression in mice. J Pharmacol Sci, 109:593-599.
17. 1A receptors in alleviating antipsychotic-induced extrapyramidal disorders. Prog Neuropsychopharmacol Biol Psychiatry, 34:877-881.
18. 1A receptor agonism in antipsychotic drug action: rationale and perspectives. Curr Opin Investig Drugs, 11:802-812.
19. Cheshire PA, Williams DR (2012). Serotonergic involvement in levodopa-induced dyskinesias in Parkinson's disease. J Clin Neurosci, 19:343-348.
20. 1A receptor agonist prevents behavioral sensitization to L-DOPA in a rodent model of Parkinson's disease. Neurosci Res, 52:185-194.
21. 1A receptor stimulation and NMDA receptor antagonism on L-DOPA-induced dyskinesia and rotational behaviors in the hemi-parkinsonian rat. Psychopharmacology (Berl), 199:99-108.
22. 1A receptor stimulation in L-DOPA-treated hemiparkinsonian rats. J Neurosci Res, 87:1645-1658.
23. Feighner JP, Boyer WF (1989). Serotonin-1A anxiolytics: an overview. Psychopathology, 22:21-26.
24. Fuller RW (1991). Role of serotonin in therapy of depression and related disorders. Journal of Clinical Psychiatry, 52:52-57.
25. Akimova E, Lanzenberger R, Kasper S (2009). The serotonin-1A receptor in anxiety disorders. Biol Psychiatry, 66:627-635.
26. 1A antagonists WAY 100635 and NAD-299 attenuate the impairment of passive avoidance caused by scopolamine in the rat. Neuropsychopharmacology, 28:253-264.
27. 1A receptors in spatial and aversive learning in the rat. Neuropharmacology, 48:830-852.
28. Madjid N, Tottie EE, Lüttgen M, Meister B, Sandin J, Kuzmin A, Stiedl O, Ogren SO (2006). 5-Hydroxytryptamine 1A receptor blockade facilitates aversive learning in mice: interactions with cholinergic and glutamatergic mechanisms. J Pharmacol Exp Ther, 316:581-591.
29. (1A) receptors in learning and memory. Behav Brain Res, 195:54-77.
30. (1A), 5-HT4 and 5-HT6 receptors in learning and memory. Trends Pharmacol Sci, 29:482-492.
31. Fabbrini G, Brotchie JM, Grandas F, Nomoto M, Goetz CG (2007). Levodopa-induced dyskinesias. Mov Disord, 22:1379-1389.
32. Pucadyil TJ, Kalipatnapu S, Chattopadhyay A (2005). The serotonin1A receptor: a representative member of the serotonin receptor family. Cell Mol Neurobiol, 25:553-580.
33. 1A agonists in the treatment of depression? Biol Psychiatry, 53:193-203.
34. Hirose A, Sasa M, Akaike A, Takaori S (1990). Inhibition of hippocampal CA1 neurons by 5-hydroxytryptamine, derived from the dorsal raphe nucleus and the 5-hydroxytryptamine1A agonist SM-3997. Neuropharmacology, 29:93-101.
35. 1A receptor ligands on rat dorso-lateral septal neurones in vitro. Br J Pharmacol, 106:893-899.
36. Hadrava V, Blier P, Dennis T, Ortemann C, de Montigny C (1995). Characterization of 5-hydroxytryptamine1A properties of flesinoxan: in vivo electrophysiology and hypothermia study. Neuropharmacology, 34:1311-1326.
37. 1A agonist, on activities of the lateral septal nucleus neurons in cats. In Takada Y, Curzon G, editors. Serotonin in the Central Nervous System and Periphery. Amsterdam: Elsevier. Science. BV, 159-165.
38. 1A receptor: G protein coupling and signalling pathways. Br J Pharmacol, 127:1751-1764.
39. Tada K, Kasamo K, Ueda N, Suzuki T, Kojima T, Ishikawa K (1999). Anxiolytic 5-hydroxytryptamine1A agonists suppress firing activity of dorsal hippocampus CA1 pyramidal neurons through a postsynaptic mechanism: single-unit study in unanesthetized, unrestrained rats. J Pharmacol Exp Ther, 288:843-848.
40. 1A receptor expression during memory formation. Psychopharmacology (Berl), 181:309-318.
41. Kusserow H, Davies B, Hörtnagl H, Voigt I, Stroh T, Bert B, Deng DR, Fink H, Veh RW, Theuring F (2004). Reduced anxiety-related behaviour in transgenic mice overexpressing serotonin 1A receptors. Brain Res Mol Brain Res, 129:104-116
42. 1A and 5-HT2A receptors are increased in Parkinson's disease neocortex. Ann N Y Acad Sci. 861:288-289.
43. 1A receptor binding in ventral visual pathways in Parkinson's disease. Mov Disord, 27:735-742.
44. 1A receptor stimulation reduces D1 receptor-induced dyskinesia and improves movement in the hemiparkinsonian rat. Neuropharmacology, 55:1321-1328.
45. (1A) receptor agonist with efficacy in experimental models of Parkinson's disease. Eur Neuropsychopharmacol, 20:582-593.
46. 1A receptor agonist-mediated protection from MPTP toxicity in mouse and macaque models of Parkinson's disease. Neurobiol Dis, 23:77-86.
47. 1A agonist improves motor complications in rodent and primate parkinsonian models. Neurology, 57:1829-1834.
48. 1A agonist, in 6-hydroxydopamine-lesioned rats. Psychopharmacology (Berl), 94:178-182.
49. (1A) receptors in rats. Pharmacol Rep, 62:258-264.
50. (1A) receptor activation improves anti-cataleptic effects of levodopa in 6-hydroxydopamine-lesioned rats. Daru, 19:338-343.
51. 1A receptor activation and anti-cataleptic effects: high-efficacy agonists maximally inhibit haloperidol-induced catalepsy. Eur J Pharmacol, 453:217-221.
52. 1A receptor agonists on patterns of rat motor activity in relation to effects on forebrain monoamine synthesis. Pharmacol Toxicol, 72:398-406.
53. 1A receptors in rats. Pharmacol Toxicol, 76:149-156.
54. Chartoff EH, Ward RP, Dorsa DM (1999). Role of adenosine and N-methyl-D-aspartate receptors in mediating haloperidol-induced gene expression and catalepsy. J Pharmacol Exp Ther, 291:531-537.
55. Steece-Collier K, Chambers LK, Jaw-Tsai SS, Menniti FS, Greenamyre JT (2000). Antiparkinsonian actions of CP-101,606, an antagonist of NR2B subunit-containing N-methyl-d-aspartate receptors. Exp Neurol, 163:239-243.
56. Hussain N, Flumerfelt BA, Rajakumar N (2001). Glutamatergic regulation of haloperidol-induced c-fos expression in the rat striatum and nucleus accumbens. Neuroscience, 102:391-399.
57. Yanahashi S, Hashimoto K, Hattori K, Yuasa S, Iyo M (2004). Role of NMDA receptor subtypes in the induction of catalepsy and increase in Fos protein expression after administration of haloperidol. Brain Res, 1011:84-93.
58. Invernizzi RW, Cervo L, Samanin R (1988). 8-Hydroxy-2-(di-n-propylamino) tetralin, a selective serotonin1A receptor agonist, blocks haloperidol-induced catalepsy by an action on raphe nuclei medianus and dorsalis. Neuropharmacology, 27:515-518.
59. 1A autoreceptors by the local application of 8-OH-DPAT reverses raclopride-induced catalepsy in the rat. Neuropharmacology, 34:495-499.
60. Wadenberg ML, Young KA, Richter JT, Hicks PB (1999). Effects of local application of 5-hydroxytryptamine into the dorsal or median raphe nuclei on haloperidol-induced catalepsy in the rat. Neuropharmacology, 38:151-156.
61. Ohno Y, Imaki J, Mae Y, Takahashi T, Tatara A (2011). Serotonergic modulation of extrapyramidal motor disorders in mice and rats: role of striatal 5-HT3 and 5-HT6 receptors. Neuropharmacology, 60:201-208.
62. Tatara A, Shimizu S, Shin N, Sato M, Sugiuchi T, Imaki J, Ohno Y (2012). Modulation of antipsychotic-induced extrapyramidal side effects by medications for mood disorders. Prog Neuropsychopharmacol Biol Psychiatry, 38:252-259.
63. Richard IH, Schiffer RB, Kurlan R (1996). Anxiety and Parkinson's disease. J Neuropsychiatry Clin Neurosci, 8:383-392.
64. 1A antagonists WAY 100635 and NAD-299 attenuate the impairment of passive avoidance caused by scopolamine in the rat. Neuropsychopharmacology, 28:253-264.
65. Madjid N, Tottie EE, Lüttgen M, Meister B, Sandin J, Kuzmin A, Stiedl O, Ogren SO (2006). 5-Hydroxytryptamine 1A receptor blockade facilitates aversive learning in mice: interactions with cholinergic and glutamatergic mechanisms. J Pharmacol Exp Ther, 316:581-591.
66. (1A) receptors in learning and memory. Behav Brain Res, 195:54-77.
67. 1A receptor agonists. Eur Neuropsychopharmacol, 20:641-654.
68. Feighner JP, Boyer WF (1989). Serotonin-1A anxiolytics: an overview. Psychopathology, 22:21-26.
69. Kataoka Y, Shibata K, Miyazaki A, Inoue Y, Tominaga K, Koizumi S, Ueki S, Niwa M (1991). Involvement of the dorsal hippocampus in mediation of the antianxiety action of tandospirone, a 5-hydroxytryptamine1A agonistic anxiolytic. Neuropharmacology, 30:475-480.
70. Shimizu H, Tatsuno T, Tanaka H, Hirose A, Araki Y, Nakamura M (1992). Serotonergic mechanisms in anxiolytic effect of tandospirone in the Vogel conflict test. Jpn J Pharmacol. 59:105-112.
71. Stefański R, Pałejko W, Kostowski W, Płaźnik A (1992). The comparison of benzodiazepine derivatives and serotonergic agonists and antagonists in two animal models of anxiety. Neuropharmacology, 31:1251-1258.
72. Parks CL, Robinson PS, Sibille E, Shenk T, Toth M (1998). Increased anxiety of mice lacking the serotonin1A receptor. Proc Natl Acad Sci U S A, 95:10734-10739.
73. Ramboz S, Oosting R, Amara DA, Kung HF, Blier P, Mendelsohn M, Mann JJ, Brunner D, Hen R (1998). Serotonin receptor 1A knockout: an animal model of anxiety-related disorder. Proc Natl Acad Sci U S A, 95:14476-14481.
74. 1A receptor. Neuropsychopharmacology, 31:101-111.
75. 1A agonists measured with the forced swim test. Psychopharmacology (Berl), 101:497-504.
76. 1A receptor antagonists. Eur J Pharmacol, 271:537-541.
77. 1A receptor activation in mice. Eur J Pharmacol, 280:235-238.
78. 1A receptor activation and antidepressant-like effects: F 13714 has high efficacy and marked antidepressant potential. Eur J Pharmacol, 420:103-112.
79. Gross C, Zhuang X, Stark K, Ramboz S, Oosting R, Kirby L, Santarelli L, Beck S, Hen R (2002). Serotonin1A receptor acts during development to establish normal anxiety-like behaviour in the adult. Nature, 416:396-400.
80. Elliott PJ, Walsh DM, Close SP, Higgins GA, Hayes AG (1990). Behavioural effects of serotonin agonists and antagonists in the rat and marmoset. Neuropharmacology, 29:949-956.
81. 1A agonist improves motor complications in rodent and primate parkinsonian models. Neurology, 57:1829-1834.
82. 1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia. Brain, 131:3380-3394.
83. 1A receptor stimulation. Neuropharmacology, 61:753-760.
84. Eskow KL, Gupta V, Alam S, Park JY, Bishop C (2007). The partial 5-HT(1A) agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy. Pharmacol Biochem Behav, 87:306-314.
85. Grégoire L, Samadi P, Graham J, Bédard PJ, Bartoszyk GD, Di Paolo T (2009). Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys. Parkinsonism Relat Disord, 15:445-452.
86. 1A receptors in the MPTP-lesioned macaque. Neurobiol Aging, 33: 9-19
87. Antonelli T, Fuxe K, Tomasini MC, Bartoszyk GD, Seyfried CA, Tanganelli S, Ferraro L (2005). Effects of sarizotan on the corticostriatal glutamate pathways. Synapse, 58:193-199.
88. (1A) antipsychotic compounds. Eur J Pharmacol, 597:34-38.